Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
vSFRGLzNWt7jEtMx
Écouter
